TRAF4‐mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis

&NA; Receptor tyrosine kinases (RTKs) are important drivers of cancers. In addition to genomic alterations, aberrant activation of WT RTKs plays an important role in driving cancer progression. However, the mechanisms underlying how RTKs drive prostate cancer remain incompletely characterized. Here we show that non‐proteolytic ubiquitination of RTK regulates its kinase activity and contributes to RTK‐mediated prostate cancer metastasis. TRAF4, an E3 ubiquitin ligase, is highly expressed in metastatic prostate cancer. We demonstrated here that it is a key player in regulating RTK‐mediated prostate cancer metastasis. We further identified TrkA, a neurotrophin RTK, as a TRAF4‐targeted ubiquitination substrate that promotes cancer cell invasion and found that inhibition of TrkA activity abolished TRAF4‐dependent cell invasion. TRAF4 promoted K27‐ and K29‐linked ubiquitination at the TrkA kinase domain and increased its kinase activity. Mutation of TRAF4‐targeted ubiquitination sites abolished TrkA tyrosine autophosphorylation and its interaction with downstream proteins. TRAF4 knockdown also suppressed nerve growth factor (NGF) stimulated TrkA downstream p38 MAPK activation and invasion‐associated gene expression. Furthermore, elevated TRAF4 levels significantly correlated with increased NGF‐stimulated invasion‐associated gene expression in prostate cancer patients, indicating that this signaling axis is significantly activated during oncogenesis. Our results revealed a posttranslational modification mechanism contributing to aberrant non‐mutated RTK activation in cancer cells.

[1]  C. Ross,et al.  Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1 , 2016, Nature Communications.

[2]  Y. Mo,et al.  Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis , 2016, Cell Death and Disease.

[3]  Jiaoti Huang,et al.  Functional screen identifies kinases driving prostate cancer visceral and bone metastasis , 2015, Proceedings of the National Academy of Sciences.

[4]  Weixin Wang,et al.  TRAF4 enhances oral squamous cell carcinoma cell growth, invasion and migration by Wnt-β-catenin signaling pathway. , 2015, International journal of clinical and experimental pathology.

[5]  D. Edwards,et al.  Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage , 2015, Stem cell reports.

[6]  Feng Wang,et al.  TRAF4 promotes the growth and invasion of colon cancer through the Wnt/β-catenin pathway. , 2015, International journal of clinical and experimental pathology.

[7]  Fan Yang,et al.  Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer , 2015, Oncotarget.

[8]  Qiqing Cai,et al.  TRAF4 Enhances Osteosarcoma Cell Proliferation and Invasion by Akt Signaling Pathway , 2014, Oncology research.

[9]  Nicholas Borcherding,et al.  Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade , 2014, Proceedings of the National Academy of Sciences.

[10]  V. Landré,et al.  Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities , 2014, Oncotarget.

[11]  C. Tomasetto,et al.  The phosphoinositide-binding protein TRAF4 modulates tight junction stability and migration of cancer cells , 2014, Tissue barriers.

[12]  Tian Xu,et al.  Rhbdd3 controls autoimmunity by suppressing the production of IL-6 by dendritic cells via K27-linked ubiquitination of the regulator NEMO , 2014, Nature Immunology.

[13]  Rachel T. Uren,et al.  Regulation of neurotrophin receptor (Trk) signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player , 2014, Front. Mol. Neurosci..

[14]  T. Sixma,et al.  Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways , 2014, Nature Structural &Molecular Biology.

[15]  David Komander,et al.  Lysine 27 Ubiquitination of the Mitochondrial Transport Protein Miro Is Dependent on Serine 65 of the Parkin Ubiquitin Ligase* , 2014, The Journal of Biological Chemistry.

[16]  P. Corn,et al.  Src signaling pathways in prostate cancer , 2014, Cancer and Metastasis Reviews.

[17]  E. Yu,et al.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy , 2014, Cancer and Metastasis Reviews.

[18]  Weiya Ma,et al.  TRAF4 is a critical molecule for Akt activation in lung cancer. , 2013, Cancer research.

[19]  K. Pienta,et al.  Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets , 2013, Proceedings of the National Academy of Sciences.

[20]  Craig Mickanin,et al.  TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. , 2013, Molecular cell.

[21]  Rong Zeng,et al.  Smurf1-Mediated Lys29-Linked Nonproteolytic Polyubiquitination of Axin Negatively Regulates Wnt/β-Catenin Signaling , 2013, Molecular and Cellular Biology.

[22]  Hua-Lin Zhou,et al.  The p97-UBXD8 complex destabilizes mRNA by promoting release of ubiquitinated HuR from mRNP. , 2013, Genes & development.

[23]  M. Hung,et al.  SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. , 2013, Genes & development.

[24]  M. Mathieu,et al.  The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. , 2012, Journal of molecular biology.

[25]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[26]  Jui‐I Chao,et al.  K63-Linked Ubiquitination in Kinase Activation and Cancer , 2012, Front. Oncol..

[27]  T. Graeber,et al.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression , 2012, Proceedings of the National Academy of Sciences.

[28]  K. Haglund,et al.  The role of ubiquitylation in receptor endocytosis and endosomal sorting , 2012, Journal of Cell Science.

[29]  N. Koibuchi,et al.  Ligand‐induced downregulation of TrkA is partly regulated through ubiquitination by Cbl , 2011, FEBS letters.

[30]  J. Kuriyan,et al.  Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. , 2011, Molecular cell.

[31]  A. Gorman,et al.  Nerve Growth Factor in Cancer Cell Death and Survival , 2011, Cancers.

[32]  R. Warrington,et al.  Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis , 2011, Cancer Immunology, Immunotherapy.

[33]  S. Grossman,et al.  Ubiquitin becomes ubiquitous in cancer , 2010, Cancer biology & therapy.

[34]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[35]  P. Spano,et al.  Nerve growth factor signaling in prostate health and disease , 2010, Growth factors.

[36]  A. Ciechanover,et al.  The 26 S Proteasome: From Basic Mechanisms to Drug Targeting* , 2009, The Journal of Biological Chemistry.

[37]  E. Tartour,et al.  Characterization of immune functions in TRAF4‐deficient mice , 2008, Immunology.

[38]  O. Larsson,et al.  Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. , 2008, Cancer research.

[39]  Aaron Ciechanover,et al.  The HECT family of E3 ubiquitin ligases: multiple players in cancer development. , 2008, Cancer cell.

[40]  Leif E. Peterson,et al.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.

[41]  M. Becich,et al.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process , 2007, BMC Cancer.

[42]  J Audouin,et al.  TRAF4 overexpression is a common characteristic of human carcinomas , 2007, Oncogene.

[43]  F. Lee,et al.  Cell Survival through Trk Neurotrophin Receptors Is Differentially Regulated by Ubiquitination , 2006, Neuron.

[44]  S. Dixon,et al.  Trk receptor binding and neurotrophin/fibroblast growth factor (FGF)-dependent activation of the FGF receptor substrate (FRS)-3. , 2006, Biochimica et biophysica acta.

[45]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[46]  M. Pierotti,et al.  Oncogenic rearrangements of the NTRK1/NGF receptor. , 2006, Cancer letters.

[47]  G. Sarosi,et al.  Subcellular targeting of oxidants during endothelial cell migration , 2005, The Journal of cell biology.

[48]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[49]  Jianxiong Jiang,et al.  Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. , 2005, Molecular cell.

[50]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Karen Lackey,et al.  Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. , 2004, Bioorganic & medicinal chemistry letters.

[52]  Yi Sun,et al.  Targeting E3 Ubiquitin Ligases for Cancer Therapy , 2003, Cancer biology & therapy.

[53]  Pier Paolo Di Fiore,et al.  Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation , 2003, Nature Cell Biology.

[54]  A. Weeraratna,et al.  Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  A. Weeraratna,et al.  Rational basis for Trk inhibition therapy for prostate cancer , 2000, The Prostate.

[56]  I. Lax,et al.  FRS2 Proteins Recruit Intracellular Signaling Pathways by Binding to Diverse Targets on Fibroblast Growth Factor and Nerve Growth Factor Receptors , 2000, Molecular and Cellular Biology.

[57]  G. Bova,et al.  Mutational analysis of the TrkA gene in prostate cancer , 1998, The Prostate.

[58]  A. Geldof,et al.  Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells , 1997, Journal of Cancer Research and Clinical Oncology.

[59]  R. Segal,et al.  Differential Utilization of Trk Autophosphorylation Sites* , 1996, The Journal of Biological Chemistry.

[60]  L. Baldi,et al.  Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IB- (*) , 1996, The Journal of Biological Chemistry.

[61]  P. Basset,et al.  Presence of a New Conserved Domain in CART1, a Novel Member of the Tumor Necrosis Factor Receptor-associated Protein Family, Which Is Expressed in Breast Carcinoma (*) , 1995, The Journal of Biological Chemistry.

[62]  M. Borrello,et al.  A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. , 1995, Genomics.

[63]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[64]  A. Ullrich,et al.  Identification of Trk binding sites for SHC and phosphatidylinositol 3'-kinase and formation of a multimeric signaling complex. , 1993, The Journal of biological chemistry.

[65]  M. Santoro,et al.  High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. , 1989, Oncogene.

[66]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[67]  B. Groner,et al.  Activation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequences. , 1988, The EMBO journal.

[68]  Feng Wang,et al.  TRAF 4 promotes the growth and invasion of colon cancer through the Wnt / β-catenin pathway , 2015 .

[69]  Craig Mickanin,et al.  TRAF 4 Promotes TGF-b Receptor Signaling and Drives Breast Cancer Metastasis , 2013 .

[70]  P. Corn,et al.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. , 2012, Future medicinal chemistry.

[71]  高橋 有我.  Ligand-induced downregulation of TrkA is partly regulated through ubiquitination by Cbl , 2011 .

[72]  E. Ricevuto,et al.  Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. , 2007, International journal of oncology.

[73]  V. Kédinger,et al.  TRAF4, the unique family member. , 2007, Advances in experimental medicine and biology.

[74]  D. Marchetti,et al.  Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostate cancer cells , 2004, Clinical & Experimental Metastasis.

[75]  L. Baldi,et al.  Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. , 1996, The Journal of biological chemistry.

[76]  M. Barbacid,et al.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences , 1986, Nature.

[77]  M. Caligiuri,et al.  Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia , 2022 .

[78]  E. Ricevuto,et al.  Tyrosine kinase inhibitor CEP-701 blocks the NTRK 1 / NGF receptor and limits the invasive capability of prostate cancer cells in vitro , 2022 .